Melatonin for Insomnia: What the Sleep Guideline Says

It recommends against it. The American Academy of Sleep Medicine's clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults states: we suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia versus no treatment in adults. The recommendation carries a WEAK strength rating under GRADE, which is the framework the guideline uses to grade its confidence in the evidence.

In GRADE, strength reflects confidence that the desirable effects outweigh the undesirable ones, not how strongly the authors feel. WEAK means the balance is close or the evidence is uncertain enough that a different reasonable person could choose differently. It is worth knowing that every drug recommendation in this guideline is WEAK, including the ones it suggests using. Melatonin is not being held to a harder standard than the prescription options it is compared against.

For sleep onset insomnia it lists zaleplon, triazolam and ramelteon. For sleep maintenance insomnia it lists suvorexant and doxepin. For both together it lists eszopiclone, zolpidem and temazepam. All of those recommendations are also WEAK. The guideline is specifically about pharmacologic treatment, so it does not address cognitive behavioural therapy for insomnia, which is generally positioned as the first-line treatment in the wider clinical literature.

No, and the distinction matters. A recommendation against use means the benefit for this indication was not established to the guideline panel's satisfaction, not that the substance was shown to be inert or harmful. Absence of demonstrated benefit and demonstrated absence of benefit are different findings, and guidelines are careful about the difference even when coverage of them is not.

Different question, and this guideline does not answer it. Its scope is chronic insomnia in adults, meaning trouble falling asleep or staying asleep as an ongoing condition. Melatonin's better-supported role is as a circadian timing signal, shifting when the body expects to sleep rather than sedating it, which is why jet lag and delayed sleep phase are discussed in a separate literature. Applying this recommendation to those situations is reading it beyond its stated scope.

The guideline's recommendation is about efficacy for a specific indication rather than about safety, and it should not be read as a safety warning. That said, melatonin is regulated as a dietary supplement in the United States rather than as a medicine, which means product content is not verified before sale in the way a drug's is, and independent testing has repeatedly found variation between labelled and actual content. Anyone pregnant, on medication, or giving it to a child should be asking a clinician rather than a label.

It was published in the Journal of Clinical Sleep Medicine in 2017, PMID 27998379. That is a fair thing to weigh: guidelines are periodically revised, and research has continued since. What has not changed is that it remains the AASM's published pharmacologic guidance on chronic insomnia in adults, and no page claiming melatonin is professionally recommended for chronic insomnia is describing this document.

This page cannot answer that, and the guideline is aimed at clinicians rather than at shoppers. What it does give you is a specific and checkable fact to bring to that decision: the professional body for sleep medicine suggests against melatonin for chronic insomnia in adults, at a weak recommendation strength. If your issue is chronic difficulty sleeping rather than a time-zone shift, that is a reason to get the problem properly assessed rather than to keep buying a different brand.